Theratechnologies Inc
TSX:TH

Watchlist Manager
Theratechnologies Inc Logo
Theratechnologies Inc
TSX:TH
Watchlist
Price: 4.47 CAD -4.89%
Market Cap: 205.5m CAD

Theratechnologies Inc
Capital Expenditures

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Theratechnologies Inc
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
Theratechnologies Inc
TSX:TH
Capital Expenditures
-$10.1m
CAGR 3-Years
-186%
CAGR 5-Years
-86%
CAGR 10-Years
N/A
Repare Therapeutics Inc
NASDAQ:RPTX
Capital Expenditures
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Capital Expenditures
-$236k
CAGR 3-Years
-7%
CAGR 5-Years
46%
CAGR 10-Years
-13%
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Capital Expenditures
-$1.3m
CAGR 3-Years
9%
CAGR 5-Years
12%
CAGR 10-Years
-1%
Willow Biosciences Inc
TSX:WLLW
Capital Expenditures
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Spectral Medical Inc
TSX:EDT
Capital Expenditures
-CA$170k
CAGR 3-Years
-9%
CAGR 5-Years
7%
CAGR 10-Years
3%
No Stocks Found

Theratechnologies Inc
Glance View

Market Cap
205.5m CAD
Industry
Biotechnology

Theratechnologies, Inc. is a pharmaceutical company. The company is headquartered in Montreal, Quebec and currently employs 87 full-time employees. The firm has two approved products: EGRIFTA SV in the United States, and Trogarzo in the United States, the European Union and the United Kingdom. EGRIFTA SV (tesamorelin for injection) is developed for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy. Trogarzo (ibalizumab-uiyk) is developed for HIV treatment. The treatment is infused every two weeks. The company is a new class of antiretrovirals (ARV), and is a long-acting ARV therapy that can lead to an undetectable viral load in combination with other ARVs. The firm markets its prescription products in the United States, Europe and Canada. Its research pipeline is focused on specialized therapies addressing unmet medical needs in HIV, oncology and non-alcoholic steatohepatitis (NASH).

TH Intrinsic Value
6.06 CAD
Undervaluation 26%
Intrinsic Value
Price

See Also

What is Theratechnologies Inc's Capital Expenditures?
Capital Expenditures
-10.1m USD

Based on the financial report for May 31, 2025, Theratechnologies Inc's Capital Expenditures amounts to -10.1m USD.

What is Theratechnologies Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-86%

Over the last year, the Capital Expenditures growth was -235%. The average annual Capital Expenditures growth rates for Theratechnologies Inc have been -186% over the past three years , -86% over the past five years .

Back to Top